


In the Claims:

Please cancel claims 1-93. Please add new claims 94-128.

Claims 1-93. **(cancelled)**

94. **(new)** A kinetic resolution process, comprising the step of reacting a silyl azide and a mixture of stereoisomers of a chiral cyclic substrate in the presence of a non-racemic chiral catalyst to produce by kinetic resolution a stereoisomerically enriched cyclic substrate or a stereoisomerically enriched azide-substituted product or both, wherein said cyclic substrate comprises a carbocycle or heterocycle having a reactive center susceptible to nucleophilic attack by said silyl azide, and said chiral catalyst comprises an asymmetric tetradentate ligand complexed with a metal atom, which complex has a rectangular planar or rectangular pyramidal geometry.
95. **(new)** The process of claim 94, wherein said silyl azide is a trialkylsilyl azide.
96. **(new)** The process of claim 94, wherein said silyl azide is trimethylsilyl azide.
97. **(new)** The process of claim 94, wherein the metal atom is a transition metal from Groups 3-12 or from the lanthanide series.
98. **(new)** The process of claim 94, wherein the metal atom is selected from the group consisting of Co, Rh, and Ir.
99. **(new)** The process of claim 94, wherein the metal atom is Co.
100. **(new)** The process of claim 94, wherein the non-racemic chiral catalyst is selected from the group consisting of chiral crown ethers complexed with a transition metal atom; the chiral catalyst represented by **102**,



in which

the substituents R_1 , R_2 , Y_1 , Y_2 , X_1 , X_2 , X_3 and X_4 each, independently, represent

hydrogen, halogens, alkyls, alkenyls, alkynyls, hydroxyl, alkoxyl, silyloxy, amino, nitro, thiol, amines, imines, amides, phosphonates, phosphines, carbonyls, carboxyls, silyls, ethers, thioethers, sulfonyls, selenoethers, ketones, aldehydes, esters, or $-(CH_2)_m-R_7$,

or any two or more of the substituents taken together form a carbocycle or heterocycle

having from 4 to 8 atoms in the ring structure, which ring structure may be a fused ring, as in the case of, for example, X_1 and X_2 forming a ring, or which ring may be a bridging ring, as in the case of R_1 and R_2 , X_2 and X_4 , or Y_1 and X_2 representing different ends of a single substituent,

with the proviso that at least one of R_1 , Y_1 , X_1 and X_2 is covalently bonded to at least one of R_2 , Y_2 , X_3 and X_4 to provide the β -iminocarbonyls as a tetradentate ligand;

R_7 represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle, or a polycycle;


m is zero or an integer in the range of 1 to 8;

M represents a transition metal;

A represents a counterion or a nucleophile; and

the catalyst is asymmetric;

the chiral catalyst represented by **108**,



in which

D₁, D₂, D₃ and D₄ each represent heterocycles, such as pyrrole, pyrrolidine, pyridine, piperidine, imidazole, pyrazine, or the like;

each R₁₈ occurring in the structure represents a bridging substituent which links adjacent heterocycles, and preferably contains at least one stereogenic center of the ligand. For example, each R₁₈ represents an alkyl, an alkenyl, an alkynyl, or -R₁₅-R₁₆-R₁₇-, wherein R₁₅ and R₁₇ each independently are absent or represent an alkyl, an alkenyl, or an alkynyl, and R₁₆ is absent or represents an amine, an imine, an amide, a phosphonate, a phosphine, a carbonyl, a carboxyl, a silyl, an oxygen, a sulfonyl, a sulfur, a selenium, or an ester;

each R₁₉, independently, is absent or represents one or more substituents of the heterocycle to which it is attached, each substituent independently selected from the group consisting of halogens, alkyls, alkenyls, alkynyls, hydroxyl, alkoxyl, silyloxy, amino, nitro, thiol amines, imines, amides, phosphonates, phosphines, carbonyls, carboxyls, silyls, ethers, thioethers, sulfonyls, selenoethers, ketones, aldehydes, esters, and -(CH₂)_m-R₇;

or any two or more of the R₁₈ and R₁₉ substituents are covalently linked to form a bridge substitution;


R₇ represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle;

m is zero or an integer in the range of 1 to 8;

M represents a transition metal; and

the catalyst is asymmetric;

the chiral catalyst represented by **112**,



in which

each of the substituents R_1 , R_2 , R_3 , R_4 , R_5 , R_{11} , R_{12} , R_{13} and R_{14} , independently, represent hydrogen, halogens, alkyls, alkenyls, alkynyls, hydroxyl, alkoxyl, silyloxy, amino, nitro, thiol amines, imines, amides, phosphonates, phosphines, carbonyls, carboxyls, silyls, ethers, thioethers, sulfonyls, selenoethers, ketones, aldehydes, esters, or $-(CH_2)_m-R_7$;

or any two or more of the substituents taken together form a carbocycle or heterocycle having at least 4 atoms in the ring structure;

R_7 represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle;


m is zero or an integer in the range of 1 to 8; and

M represents a transition metal;

if R_5 is absent, at least one of R_1 and R_2 is covalently bonded to at least one of R_3 and R_4 ; and

the catalyst is asymmetric;

the chiral catalyst represented by **114** and a complexed transition metal atom,



wherein

R₂₁ and R₂₂ each represent hydrogen, halogens, alkyls, alkenyls, alkynyls, hydroxyl, alkoxyl, silyloxy, amino, nitro, thiol amines, imines, amides, phosphonates, phosphines, carbonyls, carboxyls, silyls, ethers, thioethers, sulfonyls, selenoethers, ketones, aldehydes, esters, or $-(CH_2)_m-R_7$;

R₂₀ is absent or represents one or more substituents of the pyridine to which it is attached, each substituent independently selected from the group consisting of halogens, alkyls, alkenyls, alkynyls, hydroxyl, alkoxyl, silyloxy, amino, nitro, thiol amines, imines, amides, phosphonates, phosphines, carbonyls, carboxyls, silyls, ethers, thioethers, sulfonyls, selenoethers, ketones, aldehydes, esters, or $-(CH_2)_m-R_7$;

R₂₃ and R₂₄ each independently are absent or represent one or more substituents of the 1,3-diiminopropyl to which they are attached, each substituent independently selected from the group consisting of halogens, alkyls, alkenyls, alkynyls, hydroxyl, alkoxyl, silyloxy, amino, nitro, thiol amines, imines, amides, phosphonates, phosphines, carbonyls, carboxyls, silyls, ethers, thioethers, sulfonyls, selenoethers, ketones, aldehydes, esters, or $-(CH_2)_m-R_7$;


or any two or more of the R₂₀, R₂₁, R₂₂, R₂₃ and R₂₄ substituents are covalently linked to form a bridging substituent;

R₇ represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle; and

m is zero or an integer in the range of 1 to 8; and

the ligand is asymmetric; and

the chiral catalyst represented by 116 and a complexed transition metal atom,



in which

each of the substituents Q₈ independently, are absent or represent hydrogen or a lower alkyl;


each of R₂₅, R₂₆, R₂₇ and R₂₈, independently, represent one or more substituents on the ethyl or propyl diimine to which they are attached, which substituents are selected from the group of hydrogen, halogens, alkyls, alkenyls, alkynyls, hydroxyl, alkoxy, silyloxy, amino, nitro, thiol, amines, imines, amides, phosphonates, phosphines, carbonyls, carboxyls, silyls, ethers, thioethers, sulfonyls, selenoethers, ketones, aldehydes, esters, and $-(CH_2)_m-R_7$; or any two or more of the substituents taken together form a bridging substituent;

R₇ represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle, or a polycycle;

m is zero or an integer in the range of 1 to 8; and

the ligand is asymmetric.

101. **(new)** The process of claim 94, wherein the non-racemic chiral catalyst is represented by structure A or its enantiomer:




A

wherein

M represents Co or Co(O₂CR); and

R represents alkyl or aryl.

102. **(new)** The process of claim 101, wherein said silyl azide is a trialkylsilyl azide.
103. **(new)** The process of claim 101, wherein said silyl azide is trimethylsilyl azide.
104. **(new)** The process of claim 94, wherein the tetradentate ligand has at least one Schiff base that complexes with the metal atom.
105. **(new)** The process of claim 94, wherein the chiral catalyst has a molecular weight of less than 10,000 a.m.u.
106. **(new)** The process of claim 94, wherein the substrate is represented by the general formula **118**:



in which

Y represents O, S, N(R₅₀), C(R₅₂)(R₅₄), or has the formula A-B-C;

wherein R₅₀ represents a hydrogen, an alkyl, a carbonyl-substituted alkyl, a

carbonyl-substituted aryl, or a sulfonate, R₅₂ and R₅₄ each independently represent an electron-withdrawing group; A and C are independently absent, or represent a C₁-C₅ alkyl, O, S, carbonyl, or N(R₅₀); and B is a carbonyl, a thiocarbonyl, a phosphoryl, or a sulfonyl; and

R₃₀, R₃₁, R₃₂, and R₃₃ represent organic or inorganic substituent which form a covalent bond with the C1 or C2 carbon atoms of **118**, and which permit formation of a stable ring structure including Y.


107. **(new)** The process of claim 106, wherein the substituents R₃₀, R₃₁, R₃₂, and R₃₃ each independently represent hydrogen, halogens, alkyls, alkenyls, alkynyls, hydroxyl, amino, nitro, thiol, amines, imines, amides, phosphoryls, phosphonates, phosphines, carbonyls, carboxyls, silyls, ethers, thioethers, sulfonyls, selenoethers, ketones, aldehydes, esters, or -(CH₂)_m-R₇;

or any two or more of the substituents R₃₀, R₃₁, R₃₂, and R₃₃ taken together form a carbocyclic or heterocyclic ring having from 4 to 8 atoms in the ring structure; R₇ represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle; and

m is zero or an integer in the range of 1 to 8.

108. **(new)** The process of claim 94, wherein the cyclic substrate is selected from the group consisting of epoxides, aziridines, episulfides, cyclopropanes, cyclic carbonates, cyclic thiocarbonates, cyclic sulfates, cyclic anhydrides, cyclic phosphates, cyclic ureas, cyclic thioureas, lactams, thiolactams, lactones, thiolactones and sultones.
109. **(new)** The process of claim 94, wherein the cyclic substrate is an epoxide.
110. **(new)** The process of claim 94, wherein the cyclic substrate is a terminal epoxide.
111. **(new)** The process of claim 94, wherein the non-racemic chiral catalyst is immobilized on an insoluble matrix.

112. **(new)** The process of claim 94, wherein the cyclic substrate is immobilized on an insoluble matrix.
113. **(new)** A kinetic resolution process, comprising the step of reacting a silyl azide and a mixture of stereoisomers of a chiral cyclic substrate in the presence of a non-racemic chiral catalyst to produce by kinetic resolution a stereoisomerically enriched cyclic substrate or a stereoisomerically enriched azide-substituted product or both, wherein said cyclic substrate comprises a carbocycle or heterocycle having a reactive center susceptible to nucleophilic attack by said silyl azide, and said chiral catalyst comprises an asymmetric tridentate ligand complexed with a metal atom, which complex has a trigonal planar or trigonal pyramidal geometry.
114. **(new)** The process of claim 113, wherein said silyl azide is a trialkylsilyl azide.
115. **(new)** The process of claim 113, wherein said silyl azide is trimethylsilyl azide.
116. **(new)** The process of claim 113, wherein the metal atom is a transition metal from Groups 3-12 or from the lanthanide series.
117. **(new)** The process of claim 113, wherein the metal is selected from the group consisting of Co, Rh, and Ir.
118. **(new)** The process of claim 113, wherein the metal atom is Co.
119. **(new)** The process of claim 113, wherein the tridentate ligand has at least one Schiff base that complexes with the metal atom.
120. **(new)** The process of claim 113, wherein the catalyst has a molecular weight of less than 10,000 a.m.u.
121. **(new)** The process of claim 113, wherein the substrate is represented by the general formula:



in which

Y represents O, S, N(R₅₀), C(R₅₂)(R₅₄), or has the formula A-B-C; wherein R₅₀ represents a hydrogen, an alkyl, a carbonyl-substituted alkyl, a carbonyl-substituted aryl, or a sulfonate, R₅₂ and R₅₄ each independently represent an electron-withdrawing group; A and C are independently absent, or represent a C₁-C₅ alkyl, O, S, carbonyl, or N(R₅₀); and B is a carbonyl, a thiocarbonyl, a phosphoryl, or a sulfonyl; and

R₃₀, R₃₁, R₃₂, and R₃₃ represent organic or inorganic substituent which form a covalent bond with the C1 or C2 carbon atoms of 118, and which permit formation of a stable ring structure including Y.

122. (new) The process of claim 121, wherein the substituents R₃₀, R₃₁, R₃₂, and R₃₃ each independently represent hydrogen, halogens, alkyls, alkenyls, alkynyls, hydroxyl, amino, nitro, thiol, amines, imines, amides, phosphoryls, phosphonates, phosphines, carbonyls, carboxyls, silyls, ethers, thioethers, sulfonyls, selenoethers, ketones, aldehydes, esters, or -(CH₂)_m-R₇;

or any two or more of the substituents R₃₀, R₃₁, R₃₂, and R₃₃ taken together form a carbocyclic or heterocyclic ring having from 4 to 8 atoms in the ring structure;

R₇ represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle; and

m is zero or an integer in the range of 1 to 8.

123. (new) The process of claim 113, wherein the cyclic substrate is selected from the group consisting of epoxides, aziridines, episulfides, cyclopropanes, cyclic carbonates, cyclic thiocarbonates, cyclic sulfates, cyclic anhydrides, cyclic phosphates, cyclic ureas, cyclic thioureas, lactams, thiolactams, lactones, thiolactones, and sultones.
124. (new) The process of claim 113, wherein the cyclic substrate is an epoxide.

125. **(new)** The process of claim 113, wherein the cyclic substrate is a terminal epoxide.
126. **(new)** The process of claim 113, wherein the non-racemic chiral catalyst is immobilized on an insoluble matrix.
127. **(new)** The process of claim 113, wherein the cyclic substrate is immobilized on an insoluble matrix.
128. **(new)** The process of any of claims 94-127, wherein said cyclic substrate is racemic.

Fees

The Applicants have included a check in the amount of \$750.00 to provide for the basic filing fee for a Large Entity. The Director is hereby authorized to charge any additional required fee to our Deposit Account, 06-1448.


Conclusion

In view of the above amendments and remarks, it is believed that the pending claims are in condition for allowance. If a telephone conversation with Applicants' Attorney would expedite prosecution of the above-identified application, the Examiner is urged to contact the undersigned at (617) 832-1000.

Respectfully submitted,
Patent Group

Foley Hoag LLP
155 Seaport Boulevard
Boston, MA 02210
Telephone: (617) 832-1000
FAX: (617) 832-7000

Date: 7/7/03


Dana M. Gordon, PhD
Registration No. 44,719
Attorney for Applicants